CTRI/2024/07/070168尚未招募未知
An open label, non-invasive single centric study to validate710_Blood Pressure Monitor POC in adult population - NA
eInfoChips Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Able to provide written informed consent prior to participation in the
排除标准
- •Special populations, presence of any arrhythmia and any issues
- •during the validation procedure. Excluded subjects must be reported
- •with reasons for exclusion.
- •If K1 or K5 is not audible
- •Unable or unwilling to provide written informed consent.
- •Patients are not eligible to provide blood pressure in the opinion of the investigator.
研究者
相似试验
已完成
不适用
A single-center, open-label study to investigate the absorption, distribution, metabolism and excretion (ADME) of LEE011 after a single oral dose of 600 mg [14C]LEE011 (0.37 MBq) in healthy male subjectsgevorderde kankeradvance cancerNL-OMON40904ovartis6
已完成
不适用
A single-center, open-label study to investigate the absorption, distribution, metabolism and excretion (ADME) of HDM201 (Siremadlin) after a single oral dose of 25 mg [14C]HDM201 in healthy subjects10027656CancerNL-OMON49451ovartis Pharma AG5
已完成
不适用
A single-center, open-label study to investigate the mass balance, excretion pathways, and metabolites after a single oral dose of 500 mg, 3.7 MBq, [14C]BTZ-043 in healthy male volunteersTuberculosisNL-OMON50849niversity Hospital LMU Klinikum4
已完成
不适用
A single-center, open-label study to investigate the absorption, distribution, metabolism and excretion (ADME) of INC280 after a single oral dose of 600 mg [14C] INC280 (5.55 MBq) in healthy male subjectscancerNL-OMON41012ovartis6
进行中（未招募）
不适用
An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant TherapyEUCTR2004-004796-11-DEKlinikum Augsburg100